RecruitingPhase 1NCT07001384
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Studying ALK-negative anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Robert Stuver, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Alectinib(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2031
Study locations (7)
- Memorial Sloan Kettering Basking Ridge (LimitedProtocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
Collaborators
Genentech, Inc. · Secura Bio, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07001384 on ClinicalTrials.govOther trials for ALK-negative anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07300514Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaFudan University
- RECRUITINGPHASE2NCT07356245Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaJonathan Brammer
- RECRUITINGPHASE1NCT06176690Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasBaylor College of Medicine
- ACTIVE NOT RECRUITINGPHASE2NCT07013565Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLNew York Medical College
- RECRUITINGPHASE2NCT05996185Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaYale University
- RECRUITINGPHASE1NCT06508463Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT04925609Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid TumorsPrincess Maxima Center for Pediatric Oncology
- ACTIVE NOT RECRUITINGPHASE4NCT05160922Crizotinib Continuation Clinical StudyPfizer
See all trials for ALK-negative anaplastic large cell lymphoma →